PorTal Access, Inc., an innovative medical device company advancing vascular access technologies, today announced that the ...
Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease PURPOSE: To examine the safety, efficacy, costs, and impact on quality of life of ...
We write as clinicians and cancer survivors who underwent prolonged chemotherapy for oesophageal cancer. Our experiences highlight how access to implantable venous access devices (chemotherapy ports) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results